CAI
AZN icon

Capital Advisors Inc’s AstraZeneca AZN Stock Holding History

Capital Advisors Inc’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,218
Closed -$346K – 309
2024
Q3 		$346K Sell
2,218
-144
-6% -$23.2K 0.01% 232
2024
Q2 		$368K Buy
+2,362
New +$355K 0.01% 229

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Capital Advisors Inc's AZN Position: Q4 2024 in Review

Capital Advisors Inc sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 2,218 shares — an estimated $346K sold.

Capital Advisors Inc first reported a position in AZN in Q2 2024 and held it in 2 quarters. The position peaked at $368K in Q2 2024. 1,218 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Capital Advisors Inc reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Capital Advisors Inc sold 2,218 AstraZeneca shares in Q4 2024, an estimated $346K.
  • Capital Advisors Inc first reported a position in AstraZeneca in Q2 2024 and held it in 2 quarters.
  • Capital Advisors Inc's AstraZeneca position peaked at $368K in Q2 2024.
  • 1,218 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Capital Advisors Inc's 13F filing for Q4 2024, filed 29 Jan 2025.